Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

Efficacy and Safety of Dalbavancin As Suppressive Therapy

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT06899906
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-25T22:26:42.031881+00:00
Published At
2025-03-28T00:00:00+00:00
Record Updated At
2025-03-28
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Efficacy and Safety of Dalbavancin", "In Subjects Who Received SAT with DAL", "For Acute or Chronic Infections Between July 2019 and December 2024"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2025-03-28"
protocolSection.identificationModule.nctId
"NCT06899906"
protocolSection.identificationModule.officialTitle
"Efficacy and Safety of Dalbavancin As Suppressive Therapy"
protocolSection.statusModule.overallStatus
"RECRUITING"
protocolSection.designModule.phases
[]
protocolSection.statusModule.resultsFirstPostDateStruct.date
""

Study condition terms

  • Efficacy and Safety of Dalbavancin (protocolSection.conditionsModule.conditions)
  • In Subjects Who Received SAT with DAL (protocolSection.conditionsModule.conditions)
  • For Acute or Chronic Infections Between July 2019 and December 2024 (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.